Viral transformation for production of personalized type I interferons

Dongsheng Xu, Luwen Zhang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.

Original languageEnglish (US)
Pages (from-to)578-581
Number of pages4
JournalBiotechnology Journal
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Interferon Type I
Interferons
Virus Diseases
Human Herpesvirus 4
Hepacivirus
Cytokines

Keywords

  • Cytokine
  • Interferon
  • Personalized medicine
  • Red biotechnology
  • Type I IFNs

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Molecular Medicine

Cite this

Viral transformation for production of personalized type I interferons. / Xu, Dongsheng; Zhang, Luwen.

In: Biotechnology Journal, Vol. 5, No. 6, 01.06.2010, p. 578-581.

Research output: Contribution to journalArticle

@article{23c5978f0ab94c12b4fe48032f381e03,
title = "Viral transformation for production of personalized type I interferons",
abstract = "Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of {"}personalized{"} IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.",
keywords = "Cytokine, Interferon, Personalized medicine, Red biotechnology, Type I IFNs",
author = "Dongsheng Xu and Luwen Zhang",
year = "2010",
month = "6",
day = "1",
doi = "10.1002/biot.201000038",
language = "English (US)",
volume = "5",
pages = "578--581",
journal = "Biotechnology Journal",
issn = "1860-6768",
publisher = "Wiley-VCH Verlag",
number = "6",

}

TY - JOUR

T1 - Viral transformation for production of personalized type I interferons

AU - Xu, Dongsheng

AU - Zhang, Luwen

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.

AB - Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.

KW - Cytokine

KW - Interferon

KW - Personalized medicine

KW - Red biotechnology

KW - Type I IFNs

UR - http://www.scopus.com/inward/record.url?scp=77953153779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953153779&partnerID=8YFLogxK

U2 - 10.1002/biot.201000038

DO - 10.1002/biot.201000038

M3 - Article

VL - 5

SP - 578

EP - 581

JO - Biotechnology Journal

JF - Biotechnology Journal

SN - 1860-6768

IS - 6

ER -